PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Prime Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.83+0.36 (+10.37%)
Close on Oct 19, 2026
- Market cap
- $678.77M
- P/E (TTM)
- –
- Dividend yield
- –
Prime Medicine statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Market Cap | $694.67M | $166.30M |
| Enterprise Value | $599.57M | $87.12M |
| PB Ratio | 17.45 | 2.03 |
| P/TBV Ratio | 17.45 | 2.31 |
Income (trailing twelve months)
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Operating Income | -$196.52M | -$21.49M |
| Net Income | -$187.89M | -$22.46M |
| EBITDA | -$189.12M | -$17.14M |
| EPS (Diluted) | -$1.10 | -$0.83 |
Returns
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Return on Equity (ROE) | -373.3% | -53.2% |
| Return on Assets (ROA) | -71.2% | -41.0% |
| Return on Capital Employed (ROCE) | -90.4% | -38.0% |
Growth
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Revenue Growth (5Y CAGR) | -2.32% | 6.42% |
Balance sheet
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $95.10M | $62.64M |
| Net Cash (Debt) | $95.10M | $15.77M |
| Net Cash Per Share | $0.52 | $0.66 |
| Equity (Book Value) | $39.81M | $48.61M |
| Book Value Per Share | $0.22 | $1.36 |
| Tangible Book Value | $39.81M | $23.01M |
| Working Capital | $65.11M | $75.09M |
Financial position
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Current Ratio | 3.05 | 3.30 |
| Quick Ratio | 3.00 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Operating Cash Flow | -$156.05M | -$12.39M |
| Capital Expenditures | -$797.00K | -$1.07M |
| Free Cash Flow | -$156.85M | -$20.34M |
| FCF Per Share | -$0.86 | -$0.42 |
Efficiency
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Profits Per Employee | -$1.29M | -$705.27K |
| Employee Count | 146 | 74 |
Dividends and yields
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Earnings Yield | -27.0% | -22.8% |
| FCF Yield | -22.6% | -9.02% |
Shares
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Shares Outstanding | 181,377,000 | 58,139,000 |
| Shares Change (YoY) | 35.5% | 11.1% |
| Shares Change (QoQ) | 0.07% | 0.54% |
| Float | 147,674,000 | 49,154,900 |
| Shares Held by Insiders | 18.6% | 11.6% |
| Shares Held by Institutions | 58.8% | 59.4% |
Scores
| Measure | Prime Medicine | Industry median |
|---|---|---|
| Altman Z-Score | -5.81 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Prime Medicine's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.